NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
United Kingdom Michael Miller Ttirzepatide Mounjaro Semaglutide Wegovy Marshallh Woodworth Donga St Co
Source: prnewswire.com